Top-News
Biotechnologie USA

Vanda Pharmaceuticals Inc Aktie

Aktie
WKN:  A0JJT3 ISIN:  US9216591084 US-Symbol:  VNDA
4,51 $
+0,07 $
+1,58%
3,9808 € 17:40:55 Uhr
Depot/Watchlist
Aktienanzahl *
58,31 Mio.
Marktkapitalisierung *
232,64 Mio. €
Streubesitz
18,38%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 27.01.2025

Vanda Pharmaceuticals Inc News

08:46 Uhr - PR Newswire
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 PR Newswire
23.04.25 - PR Newswire
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA PR Newswire
07.04.25 - PR Newswire
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting PR Newswire
31.03.25 - PR Newswire
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia PR Newswire
24.02.25 - PR Newswire
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-​Marie-Tooth disease type 2S" PR Newswire
13.02.25 - PR Newswire
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
05.02.25 - PR Newswire
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 PR Newswire
03.02.25 - PR Newswire
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist PR Newswire
27.01.25 - PR Newswire
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis PR Newswire
08.01.25 - PR Newswire
Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review PR Newswire
20.12.24 - PR Newswire
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia ...
12.11.24 - PR Newswire
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences PR Newswire
06.11.24 - PR Newswire
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire
02.11.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
30.10.24 - PR Newswire
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 PR Newswire
25.10.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
17.10.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
14.10.24 - PR Newswire
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-​Binding Proposal from Cycle Group Holdings Ltd. PR Newswire
09.10.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
03.10.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire

Newssuche

Videos

newspaper
30.04.25 +13,48%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »